Latest Breaking News On - Athimalaipet ramanan - Page 7 : comparemela.com

Science’s COVID-19 reporting is supported by the Heising-Simons Foundation. The world’s largest trial of COVID-19 drugs has produced more good news: The anti-inflammatory drug tocilizumab cut the death risk of people hospitalized with the disease, reduced their need for a mechanical ventilator, and shortened time spent in the hospital, investigators of the United Kingdom’s Recovery trial announced today at a press conference. A preprint about the data has been published on medRxiv. “This is an incredibly significant result,” says Athimalaipet Ramanan, a rheumatologist at the University of Bristol who was not involved in the study but sits on the steering committee of a tocilizumab trial in India. “This is probably only the second drug that has an impact on mortality,” he says, after the steroid dexamethasone. If the data pan out, it’s “fantastic news,” adds Jason Pogue, a pharmacist at the University of Michigan, Ann Arbor, and president of the Society of Infect

United statesCity ofUnited kingdomAnn arborPeter horbyMarc bruxelle alamyKai kupferschmidtJason pogueAshish jhaMartin landrayAthimalaipet ramananHeising simons foundationMultifactorial adaptive platform trial for communitySociety of infectious diseases pharmacistsUniversity school of public healthUniversity of bristol